Tufia Haddad, MD
Medical Oncology · Rochester, MNNPI 1215062989
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,000 of the $5,763 with a category attached, or 86.8%. Puma Biotechnology, Inc. accounts for 90.6% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $2,983, more than ten times the $172 reported in 2021.
Across 14 payments — averaging $411.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Puma Biotechnology, Inc.$5K
- Taiho Oncology, Inc.$194
- AstraZeneca$191
- E.r. Squibb & Sons, L.L.C.$103
- Menarini Silicon Biosystems, Inc.$54
Across 53 payments — averaging $72,142 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$2.7M
- Puma Biotechnology, Inc.$965K
- GSK$121K
- Genentech, Inc.$26K
- EMD Serono, Inc.$18K
What the payments were for
- Consulting fees$5,00087%
- Speaking & faculty fees$4227%
- Travel & lodging$661%
- Food & beverage$2755%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Puma Biotechnology, Inc. | 4 | $5,221 |
| Taiho Oncology, Inc. | 4 | $194 |
| AstraZeneca | 4 | $191 |
| E.r. Squibb & Sons, L.L.C. | 1 | $103 |
| Menarini Silicon Biosystems, Inc. | 1 | $54 |
How this compares
$5,763 in reported general payments places this provider in the 60th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 28 | $500 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Rochester
- Amit MahipalRochester$746K
- Alton SartorRochester$688K
- Ben GeorgeRochester$579K
- Elisabeth HeathRochester$236K
- Matthew GoetzRochester$136K
- Thorvardur HalfdanarsonRochester$86K
- Harry YoonRochester$69K
- Karthik GiridharRochester$66K
- Joleen HubbardRochester$59K
- Lionel Aurelien Kankeu FonkouaRochester$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.